Cytarabine; Daunorubicin Patent Expiration

Cytarabine; Daunorubicin is used for treating newly-diagnosed therapy-related acute myeloid leukemia (T-AML) or AML with myelodysplasia-related changes (AML-MRC) in children and adults. It was first introduced by Celator Pharmaceuticals Inc in its drug Vyxeos on Aug 3, 2017.


Cytarabine; Daunorubicin Patents

Given below is the list of patents protecting Cytarabine; Daunorubicin, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Vyxeos US10028912 Method of lyophilizing liposomes Oct 15, 2032 Celator Pharms
Vyxeos US10166184 Method of lyophilizing liposomes Oct 15, 2032 Celator Pharms
Vyxeos US10835492 Method of lyophilizing liposomes Oct 15, 2032 Celator Pharms
Vyxeos US8092828 Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders Apr 01, 2029 Celator Pharms
Vyxeos US8022279 Liposomal formulations of anthracycline agents and cytidine analogs Sep 14, 2027 Celator Pharms
Vyxeos US7850990 Compositions for delivery of drug combinations Jan 23, 2027 Celator Pharms
Vyxeos US9271931 Compositions for delivery of drug combinations Jan 23, 2027 Celator Pharms
Vyxeos US8518437 Lipid carrier compositions with enhanced blood stability Jun 07, 2026 Celator Pharms
Vyxeos US8431806 Liposomal formulations of anthracycline agents and cytidine analogs Apr 22, 2025 Celator Pharms



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Cytarabine; Daunorubicin's patents.

Given below is the list recent legal activities going on the following patents of Cytarabine; Daunorubicin.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 4th Year, Large Entity 01 May, 2024 US10835492
Payment of Maintenance Fee, 12th Year, Large Entity 28 Jun, 2023 US8092828
Payment of Maintenance Fee, 12th Year, Large Entity 08 Mar, 2023 US8022279
Correspondence Address Change 07 Mar, 2023 US8518437
Correspondence Address Change 27 Feb, 2023 US8431806
Correspondence Address Change 27 Feb, 2023 US8092828
Email Notification 03 Jan, 2023 US10835492
Change in Power of Attorney (May Include Associate POA) 03 Jan, 2023 US10028912
Change in Power of Attorney (May Include Associate POA) 03 Jan, 2023 US8092828
Email Notification 03 Jan, 2023 US10166184


Cytarabine; Daunorubicin's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List